| Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Early Breast Cancer Trialists' Collaborative Group The Lancet 365 (9472), 1687-1717, 2005 | 7462 | 2005 |
| Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials Early Breast Cancer Trialists' Collaborative Group The Lancet 366 (9503), 2087-2106, 2005 | 5906 | 2005 |
| Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 … Early Breast Cancer Trialists' Collaborative Group The Lancet 378 (9804), 1707-1716, 2011 | 3536 | 2011 |
| Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials EBCTC Group The lancet 378 (9793), 771-784, 2011 | 3421* | 2011 |
| Everolimus for advanced pancreatic neuroendocrine tumors JC Yao, MH Shah, T Ito, CL Bohas, EM Wolin, E Van Cutsem, TJ Hobday, ... New England Journal of Medicine 364 (6), 514-523, 2011 | 3192 | 2011 |
| Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women … Early Breast Cancer Trialists' Collaborative Group Lancet 383 (9935), 2014 | 1688 | 2014 |
| iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics L Seymour, J Bogaerts, A Perrone, R Ford, LH Schwartz, S Mandrekar, ... The Lancet Oncology 18 (3), e143-e152, 2017 | 1686 | 2017 |
| RECIST 1.1—Update and clarification: From the RECIST committee LH Schwartz, S Litière, E De Vries, R Ford, S Gwyther, S Mandrekar, ... European journal of cancer 62, 132-137, 2016 | 1228 | 2016 |
| 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years H Pan, R Gray, J Braybrooke, C Davies, C Taylor, P McGale, R Peto, ... New England Journal of Medicine 377 (19), 1836-1846, 2017 | 1184 | 2017 |
| Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials Early Breast Cancer Trialists' Collaborative Group The Lancet 386 (10001), 1341-1352, 2015 | 1147 | 2015 |
| Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo … ME Pavel, JD Hainsworth, E Baudin, M Peeters, D Hörsch, RE Winkler, ... The Lancet 378 (9808), 2005-2012, 2011 | 1139 | 2011 |
| Overexpression of a Mr 110,000 Vesicular Protein in Non-P-Glycoprotein-mediated Multidrug Resistance RJ Scheper, HJ Broxterman, GL Scheffer, P Kaaijk, WS Dalton, ... Cancer research 53 (7), 1475-1479, 1993 | 826 | 1993 |
| Biodistribution of 89Zr‐trastuzumab and PET Imaging of HER2‐Positive Lesions in Patients With Metastatic Breast Cancer EC Dijkers, TH Oude Munnink, JG Kosterink, AH Brouwers, PL Jager, ... Clinical Pharmacology & Therapeutics 87 (5), 586-592, 2010 | 823 | 2010 |
| A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical … NI Cherny, R Sullivan, U Dafni, JM Kerst, A Sobrero, C Zielinski, ... Annals of Oncology 26 (8), 1547-1573, 2015 | 803 | 2015 |
| Evidence based selection of housekeeping genes HJM de Jonge, RSN Fehrmann, ESJM de Bont, RMW Hofstra, F Gerbens, ... PloS one 2 (9), e898, 2007 | 797 | 2007 |
| Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. M Müller, C Meijer, GJ Zaman, P Borst, RJ Scheper, NH Mulder, ... Proceedings of the National Academy of Sciences 91 (26), 13033-13037, 1994 | 775 | 1994 |
| Radiolabeled amino acids: basic aspects and clinical applications in oncology PL Jager, W Vaalburg, J Pruim, EGE de Vries, KJ Langen, DA Piers Journal of nuclear medicine 42 (3), 432-445, 2001 | 743 | 2001 |
| Response assessment criteria for brain metastases: proposal from the RANO group NU Lin, EQ Lee, H Aoyama, IJ Barani, DP Barboriak, BG Baumert, ... The lancet oncology 16 (6), e270-e278, 2015 | 710 | 2015 |
| A review on CXCR4/CXCL12 axis in oncology: no place to hide UM Domanska, RC Kruizinga, WB Nagengast, H Timmer-Bosscha, ... European journal of cancer 49 (1), 219-230, 2013 | 672 | 2013 |
| Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials Early Breast Cancer Trialists' Collaborative Group The Lancet 386 (10001), 1353-1361, 2015 | 587 | 2015 |
de Jong SProfessor of Preclinical and Translational Oncology, University Medical Center Groningen在 umcg.nl 的电子邮件经过验证
